EUVIMEDEUVIMED entdecken
Systematische ÜbersichtÜbersichtsarbeitUmbrella Review

De‐Escalation Treatment Strategies in HPV ‐Positive Oropharyngeal Squamous Cell Carcinoma: An Umbrella Review of Systematic Reviews and Meta‐Analyses

Fausto Petrelli iD, Francesca Trevisan, Agostina De Stefani, Lorenza Bruschieri, Valentina Riboldi, Massimiliano Nardone, Daniele Spada, Angela Gasparini, Chiara Bramati, Mara Ghilardi, Paolo Bossi

Head & Neck · 2026-08 · 48 (8) · 2281-2289

DOI: 10.1002/hed.70340 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Head & Neck, online erschienen am 02.06.2026. Verfasst von Fausto Petrelli und 10 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Unit, ASST Bergamo Ovest, Treviglio, Bergamo, Italy. Hauptthemen laut MEDLINE: Oropharyngeal Neoplasms, Papillomavirus Infections, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell. Die Arbeit nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

De‐escalation strategies for human papillomavirus (HPV)‐positive oropharyngeal squamous cell carcinoma (OPSCC) aim to reduce late morbidity while preserving cure rates, but evidence syntheses provide inconsistent conclusions and may be affected by overlap of primary studies.

Methods

We performed an umbrella review of systematic reviews (SRs) and meta‐analyses (MAs) evaluating de‐escalation approaches versus standard‐of‐care therapy in HPV‐positive (or p16‐positive) OPSCC. MEDLINE (PubMed), Embase, and the Cochrane Database of SRs were searched from inception to December 1, 2025. Two reviewers independently screened records and extracted data. Overlap among included SR/MAs was quantified using the corrected covered area (CCA); when overlap was substantial, an index review was prioritized based on methodological quality, recency, and completeness of outcomes. Review‐level quality and risk of bias were assessed using AMSTAR‐2 and ROBIS. Strength of evidence was graded with a restricted Ioannidis‐style framework ( p ‐value + sample‐size thresholds). Outcomes included overall survival (OS), progression‐free survival (PFS), locoregional control (LRC), distant control, and acute/late toxicity.

Results

Evidence clustered into four domains. (1) Definitive systemic substitution: an RCT‐only index MA (five trials; n = 1560) showed that replacing cisplatin with cetuximab during definitive radiotherapy was associated with inferior OS (HR: 2.83; 95% CI: 1.22–6.57) and inferior LRC (HR: 2.78; 95% CI: 1.77–4.39), without a statistically significant reduction in late grade ≥ 3 toxicity (RR: 0.63; 95% CI: 0.36–1.10). The two RCT‐only syntheses were fully overlapping (CCA, 100%). (2) Broad de‐intensification: across 55 studies ( n = 38 929), de‐intensified strategies were associated with worse OS (HR: 1.33; 95% CI: 1.17–1.52), PFS (HR: 2.11; 95% CI: 1.65–2.69), LRC (HR: 2.51; 95% CI: 1.75–3.59), and distant control (HR: 1.90; 95% CI: 1.25–2.90). (3) Post‐transoral surgery adjuvant de‐intensification: at the time of the Cochrane review (2018), no completed eligible RCTs were identified; updated trial‐level data are now available (ADEPT closed early; ECOG‐E3311 long‐term follow‐up published in 2025; PATHOS phase III enrollment completing in 2025). (4) Reduced‐dose radiotherapy: evidence remains limited to a registered protocol.

Conclusions

In cisplatin‐eligible HPV‐positive OPSCC, cetuximab substitution compromises oncologic outcomes without reliable severe late‐toxicity reduction; other de‐escalation approaches should remain trial‐based until robust patient‐reported and functional data demonstrate a meaningful net benefit.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oropharyngeal NeoplasmsPapillomavirus InfectionsSquamous Cell Carcinoma of Head and NeckCarcinoma, Squamous CellHumansSystematic Reviews as TopicMeta-Analysis as TopicHuman Papillomavirus Viruses

Autor:innen und Institutionen

  • Oncology Unit, ASST Bergamo Ovest, Treviglio, Bergamo, Italy.
  • Radiotherapy Unit, ASST Bergamo Ovest, Treviglio, Bergamo, Italy.
  • Otorhinolaryngology Unit, ASST Bergamo Ovest, Treviglio, Bergamo, Italy.
  • Department of Biomedical Sciences, Humanitas University, Milan, Italy.
  • IRCCS Humanitas Research Hospital, Milan, Italy.

ORCID-Profile: Fausto Petrelli

Zitieren

APA

Petrelli, F., Trevisan, F., De Stefani, A., Bruschieri, L., Riboldi, V., Nardone, M., Spada, D., Gasparini, A., Bramati, C., Ghilardi, M., & Bossi, P. (2026). De‐Escalation Treatment Strategies in HPV ‐Positive Oropharyngeal Squamous Cell Carcinoma: An Umbrella Review of Systematic Reviews and Meta‐Analyses. Head & Neck, 48(8), 2281-2289. https://doi.org/10.1002/hed.70340

Vancouver

Petrelli F, Trevisan F, De Stefani A, Bruschieri L, Riboldi V, Nardone M, et al. De‐Escalation Treatment Strategies in HPV ‐Positive Oropharyngeal Squamous Cell Carcinoma: An Umbrella Review of Systematic Reviews and Meta‐Analyses. Head & Neck. 2026;48(8):2281-2289. doi:10.1002/hed.70340

BibTeX
@article{Petrelli2026,
  author = {Petrelli, Fausto and Trevisan, Francesca and De Stefani, Agostina and Bruschieri, Lorenza and Riboldi, Valentina and Nardone, Massimiliano and Spada, Daniele and Gasparini, Angela and Bramati, Chiara and Ghilardi, Mara and Bossi, Paolo},
  title = {De‐Escalation Treatment Strategies in HPV ‐Positive Oropharyngeal Squamous Cell Carcinoma: An Umbrella Review of Systematic Reviews and Meta‐Analyses},
  journal = {Head & Neck},
  year = {2026},
  volume = {48},
  number = {8},
  pages = {2281--2289},
  doi = {10.1002/hed.70340}
}
Kostenlos starten →